Insider Selling: Cellebrite DI (NASDAQ:CLBT) CRO Sells 12,658 Shares of Stock

Cellebrite DI Ltd. (NASDAQ:CLBT – Get Free Report) CRO Marcus Jewell sold 12,658 shares of Cellebrite DI stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $12.77, for a total transaction of $161,642.66. Following the sale, the executive directly owned 440,101 shares of the company’s stock, valued at $5,620,089.77. This represents a 2.80% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Marcus Jewell also recently made the following trade(s):

Get Cellebrite DI alerts:

• On Tuesday, May 12th, Marcus Jewell sold 383 shares of Cellebrite DI stock. The stock was sold at an average price of $13.01, for a total value of $4,982.83.

Cellebrite DI Stock Up 5.0%

CLBT opened at $13.63 on Tuesday. The stock’s fifty day moving average is $13.51 and its two-hundred day moving average is $15.48. The company has a market capitalization of $3.40 billion, a P/E ratio of 48.68, a PEG ratio of 1.99 and a beta of 1.15. Cellebrite DI Ltd. has a 52 week low of $11.02 and a 52 week high of $19.98.

Institutional Investors Weigh In On Cellebrite DI

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. CWM LLC increased its holdings in shares of Cellebrite DI by 85.7% during the third quarter. CWM LLC now owns 1,560 shares of the company’s stock valued at $29,000 after acquiring an additional 720 shares in the last quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA boosted its holdings in Cellebrite DI by 81.0% in the fourth quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock valued at $34,000 after purchasing an additional 850 shares during the last quarter. Advisory Services Network LLC acquired a new position in Cellebrite DI in the third quarter valued at approximately $40,000. First Horizon Corp increased its holdings in shares of Cellebrite DI by 421.8% during the 4th quarter. First Horizon Corp now owns 2,891 shares of the company’s stock valued at $52,000 after purchasing an additional 2,337 shares in the last quarter. Finally, Vestcor Inc acquired a new position in shares of Cellebrite DI in the 3rd quarter valued at $70,000. 45.88% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have issued reports on CLBT shares. Wall Street Zen raised Cellebrite DI from a “sell” rating to a “hold” rating in a research report on Sunday, March 15th. Needham & Company LLC cut their target price on Cellebrite DI from $18.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Cellebrite DI presently has a consensus rating of “Moderate Buy” and an average price target of $21.75.

View Our Latest Research Report on Cellebrite DI

About Cellebrite DI

(Get Free Report)

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.

Featured Articles

• Five stocks we like better than Cellebrite DI
• Does Nano Nuclear Energy’s New Deal Amp the Outlook?
• 3 Dividend Stocks With Insiders Buying in 2026
• Dillard’s Posted a Huge Earnings Beat—So Why Did the Rally Fade?
• Why Trump’s Amazon Stock Sale May Not Matter at All

Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.